Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study
Lindberg, Gunnar LU ; Lindblad, Ulf LU ; Löw-Larsen, Bent ; Merlo, Juan LU
; Melander, Arne
LU
and Råstam, Lennart
LU
(2002)
In Pharmacoepidemiology and Drug Safety
11(6).
p.493-497
- Abstract
- Abstract
Purpose
Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).
Methods
All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.
Results
Two hundred and fourteen patients on CCB and 1029 on other AHD were identified.... (More) - Abstract
Purpose
Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).
Methods
All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.
Results
Two hundred and fourteen patients on CCB and 1029 on other AHD were identified. Overall mortality and the combined mortality from myocardial infarction and stroke were higher in CCB users; hazard ratios adjusted for sex, age, co-morbidity and other and risk factors were 1.84 (95% CI 1.25-2.72) and 2.37 (95% CI 1.27-4.44), respectively. The risk estimates for cancer mortality and for cancer incidence did not differ significantly.
Conclusions
Results from clinical trials as well as observational studies, including the present one, indicate a higher mortality risk and a higher cardiovascular morbidity risk associated with use of CCB. Accordingly, CCB should not be regarded as first line drugs in hypertension. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/123260
- author
- Lindberg, Gunnar
LU
; Lindblad, Ulf
LU
; Löw-Larsen, Bent
; Merlo, Juan
LU
; Melander, Arne
LU
and Råstam, Lennart
LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pharmacoepidemiology and Drug Safety
- volume
- 11
- issue
- 6
- pages
- 493 - 497
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000178751100009
- pmid:12426934
- scopus:0036750064
- ISSN
- 1053-8569
- DOI
- 10.1002/pds.737
- language
- English
- LU publication?
- yes
- id
- b8d15ae3-e4d1-4087-ba3f-d4dbf0134b69 (old id 123260)
- date added to LUP
- 2016-04-04 10:22:01
- date last changed
- 2022-01-29 20:09:58
@article{b8d15ae3-e4d1-4087-ba3f-d4dbf0134b69,
abstract = {{Abstract<br/><br>
<br/><br>
Purpose<br/><br>
Treatment with blood pressure lowering drugs may reduce morbidity and mortality. However, the efficacy and effectiveness may differ between antihypertensive agents. The current investigation aimed to compare mortality and cancer incidence in hypertensive patients treated with calcium channel blockers (CCB) or with other antihypertensive drugs (AHD).<br/><br>
<br/><br>
Methods<br/><br>
All patients in two outpatient clinics treated with AHD who underwent an annual check-up during 1989 or 1990 were selected. Fatal events were identified through 1997 and incident cancers through 1998.<br/><br>
<br/><br>
Results<br/><br>
Two hundred and fourteen patients on CCB and 1029 on other AHD were identified. Overall mortality and the combined mortality from myocardial infarction and stroke were higher in CCB users; hazard ratios adjusted for sex, age, co-morbidity and other and risk factors were 1.84 (95% CI 1.25-2.72) and 2.37 (95% CI 1.27-4.44), respectively. The risk estimates for cancer mortality and for cancer incidence did not differ significantly.<br/><br>
<br/><br>
Conclusions<br/><br>
Results from clinical trials as well as observational studies, including the present one, indicate a higher mortality risk and a higher cardiovascular morbidity risk associated with use of CCB. Accordingly, CCB should not be regarded as first line drugs in hypertension.}},
author = {{Lindberg, Gunnar and Lindblad, Ulf and Löw-Larsen, Bent and Merlo, Juan and Melander, Arne and Råstam, Lennart}},
issn = {{1053-8569}},
language = {{eng}},
number = {{6}},
pages = {{493--497}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Pharmacoepidemiology and Drug Safety}},
title = {{Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study}},
url = {{http://dx.doi.org/10.1002/pds.737}},
doi = {{10.1002/pds.737}},
volume = {{11}},
year = {{2002}},
}